|

Proteomics in Small Cell Lung Cancer

RECRUITINGSponsored by Aalborg University Hospital
Actively Recruiting
SponsorAalborg University Hospital
Started2023-03-01
Est. completion2025-12
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05623956

Summary

The aim of this study is to gather insight into tumor-derived circulating extracellular vesicles-proteins in patients with newly diagnosed small cell lung cancer.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Written and signed informed consent
* Histopathologically and/or cytologically newly-diagnosed SCLC
* Measurable disease on CT scans
* Eligibility to receive standard chemotherapy consisting of carboplatin and etoposide

Exclusion Criteria:

* Active biopsy-verified second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ
* Prior treatment for any malignant diseases other than non-melanoma skin cancer and cervical carcinoma in situ
* Concomitant anticoagulation treatment (acetylsalicylic acid and clopidogrel are allowed)
* Treatment with any other investigational agent

Conditions3

CancerLung CancerSmall Cell Lung Cancer

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.